# Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.

> **NCT06498037** · PHASE4 · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 45 (estimated)

## Conditions studied

- Cancer Pain

## Interventions

- **DRUG:** Fentanyl

## Key facts

- **NCT ID:** NCT06498037
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-23
- **Primary completion:** 2025-11-01
- **Final completion:** 2025-12-02
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06498037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06498037, "Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06498037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*